HEADER TRANSFERASE 01-AUG-10 2XNB TITLE DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) TITLE 2 PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS COMPND MOL_ID: 1; COMPND 2 MOLECULE: CELL DIVISION PROTEIN KINASE 2; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: P33 PROTEIN KINASE; COMPND 5 EC: 2.7.11.22; COMPND 6 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 6 EXPRESSION_SYSTEM_COMMON: FALL ARMYWORM; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 7108; SOURCE 8 EXPRESSION_SYSTEM_CELL_LINE: SF9; SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: BACULOVIRUS KEYWDS CELL CYCLE, TRANSFERASE, CDK9 INHIBITOR EXPDTA X-RAY DIFFRACTION AUTHOR S.WANG,G.GRIFFITHS,C.A.MIDGLEY,A.L.BARNETT,M.COOPER,J.GRABAREK, AUTHOR 2 L.INGRAM,W.JACKSON,G.KONTOPIDIS,S.J.MCCLUE,C.MCINNES,J.MCLACHLAN, AUTHOR 3 C.MEADES,M.MEZNA,I.STUART,M.P.THOMAS,D.I.ZHELEVA,D.P.LANE, AUTHOR 4 R.C.JACKSON,D.M.GLOVER,D.G.BLAKE,P.M.FISCHER REVDAT 3 20-DEC-23 2XNB 1 REMARK REVDAT 2 28-MAR-12 2XNB 1 SOURCE JRNL REMARK VERSN REVDAT 1 10-NOV-10 2XNB 0 JRNL AUTH S.WANG,G.GRIFFITHS,C.A.MIDGLEY,A.L.BARNETT,M.COOPER, JRNL AUTH 2 J.GRABAREK,L.INGRAM,W.JACKSON,G.KONTOPIDIS,S.J.MCCLUE, JRNL AUTH 3 C.MCINNES,J.MCLACHLAN,C.MEADES,M.MEZNA,I.STUART,M.P.THOMAS, JRNL AUTH 4 D.I.ZHELEVA,D.P.LANE,R.C.JACKSON,D.M.GLOVER,D.G.BLAKE, JRNL AUTH 5 P.M.FISCHER JRNL TITL DISCOVERY AND CHARACTERISATION OF JRNL TITL 2 2-ANILINO-4-(THIAZOL-5-YL)PYRIMIDINE TRANSCRIPTIONAL CDK JRNL TITL 3 INHIBITORS AS ANTICANCER AGENTS JRNL REF CHEM.BIOL. V. 17 1111 2010 JRNL REFN ISSN 1074-5521 JRNL PMID 21035734 JRNL DOI 10.1016/J.CHEMBIOL.2010.07.016 REMARK 2 REMARK 2 RESOLUTION. 1.85 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.5.0109 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.85 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 30.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 98.7 REMARK 3 NUMBER OF REFLECTIONS : 22795 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.216 REMARK 3 R VALUE (WORKING SET) : 0.213 REMARK 3 FREE R VALUE : 0.294 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 3.300 REMARK 3 FREE R VALUE TEST SET COUNT : 766 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.85 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 1.90 REMARK 3 REFLECTION IN BIN (WORKING SET) : 1661 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 99.65 REMARK 3 BIN R VALUE (WORKING SET) : 0.4500 REMARK 3 BIN FREE R VALUE SET COUNT : 60 REMARK 3 BIN FREE R VALUE : 0.4770 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2379 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 27 REMARK 3 SOLVENT ATOMS : 260 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 39.29 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.66000 REMARK 3 B22 (A**2) : 2.33000 REMARK 3 B33 (A**2) : -1.68000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.196 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.193 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.189 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 6.508 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.962 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.918 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 2612 ; 0.012 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): 1839 ; 0.003 ; 0.020 REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 3563 ; 1.689 ; 1.999 REMARK 3 BOND ANGLES OTHERS (DEGREES): 4454 ; 0.943 ; 3.002 REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 323 ; 8.852 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 112 ;41.472 ;22.768 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 468 ;21.963 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 20 ;24.623 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 391 ; 0.126 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 2852 ; 0.017 ; 0.021 REMARK 3 GENERAL PLANES OTHERS (A): 534 ; 0.001 ; 0.020 REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 1527 ; 3.229 ; 1.500 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): 603 ; 1.146 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 2502 ; 4.610 ; 2.000 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 1085 ; 6.294 ; 3.000 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 1046 ; 8.205 ; 4.500 REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : BABINET MODEL WITH MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.20 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS. RESIDUES 340-42 ARE DISORDED. DISORDERED REGIONS WERE REMARK 3 MODELED STEREOCHEMICALLY 13-18, 147-163. REMARK 4 REMARK 4 2XNB COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 01-AUG-10. REMARK 100 THE DEPOSITION ID IS D_1290044888. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 30-JUL-04 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 6.8 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU FR-D REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : BLUE MAX-FLUX CONFOCAL REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : RIGAKU IMAGE PLATE REMARK 200 INTENSITY-INTEGRATION SOFTWARE : D*TREK REMARK 200 DATA SCALING SOFTWARE : D*TREK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 25565 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.800 REMARK 200 RESOLUTION RANGE LOW (A) : 31.880 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.8 REMARK 200 DATA REDUNDANCY : 2.630 REMARK 200 R MERGE (I) : 0.08000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 7.3000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.80 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.86 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.1 REMARK 200 DATA REDUNDANCY IN SHELL : 2.56 REMARK 200 R MERGE FOR SHELL (I) : 0.48000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.100 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: MOLREP REMARK 200 STARTING MODEL: PDB ENTRY 2CLX REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 32.50 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 1.84 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 10% PEG 3350, NAF, PH 7.0, PH 6.8 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 26.50250 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 36.01400 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 35.55400 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 36.01400 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 26.50250 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 35.55400 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 THR A 41 REMARK 465 GLU A 42 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLU A 40 CD OE1 OE2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 CG2 ILE A 135 CD1 ILE A 141 2.08 REMARK 500 O HOH A 2047 O HOH A 2048 2.13 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 LEU A 267 CB - CG - CD1 ANGL. DEV. = 10.4 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 THR A 14 -48.90 59.83 REMARK 500 ASP A 38 -19.55 -41.55 REMARK 500 PRO A 45 140.16 -39.17 REMARK 500 GLU A 73 -129.05 51.10 REMARK 500 ARG A 126 -18.04 85.82 REMARK 500 ASP A 127 49.30 -144.11 REMARK 500 ASP A 145 53.28 73.43 REMARK 500 THR A 158 -169.73 52.70 REMARK 500 HIS A 161 -4.21 86.67 REMARK 500 TYR A 179 50.48 -105.43 REMARK 500 LEU A 255 136.89 -38.49 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 ASN A 74 LYS A 75 -134.64 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: MAIN CHAIN PLANARITY REMARK 500 REMARK 500 THE FOLLOWING RESIDUES HAVE A PSEUDO PLANARITY REMARK 500 TORSION ANGLE, C(I) - CA(I) - N(I+1) - O(I), GREATER REMARK 500 10.0 DEGREES. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 500 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 500 I=INSERTION CODE). REMARK 500 REMARK 500 M RES CSSEQI ANGLE REMARK 500 LEU A 175 10.03 REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH A2039 DISTANCE = 6.83 ANGSTROMS REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE Y8L A 1299 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1PYE RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR REMARK 900 RELATED ID: 1H08 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 2VTH RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2B53 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN-234325 REMARK 900 RELATED ID: 1V1K RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1KE7 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2,2-DIOXIDO-1, REMARK 900 3-DIHYDRO-2- BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3- OXAZOL-5-YL)- REMARK 900 1,3-DIHYDRO-2H-INDOL-2-ONE REMARK 900 RELATED ID: 1OKV RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ILE-PHE-NH2 REMARK 900 RELATED ID: 1H25 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 E2F REMARK 900 RELATED ID: 1PXK RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)PYRIMIDIN-2-YL]-N'- HYDROXYIMINOFORMAMIDE REMARK 900 RELATED ID: 2WIH RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125 REMARK 900 RELATED ID: 2BHH RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 4- HYDROXYPIPERINDINESULFONYL-INDIRUBINE REMARK 900 RELATED ID: 2VTA RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2UUE RELATED DB: PDB REMARK 900 REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE REMARK 900 INHIBITORS REMARK 900 RELATED ID: 1GZ8 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2- REMARK 900 AMINO-6-(3'-METHYL- 2'-OXO)BUTOXYPURINE REMARK 900 RELATED ID: 1E1V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058 REMARK 900 RELATED ID: 1OL2 RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1H27 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P27 REMARK 900 RELATED ID: 1JSV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH 4- REMARK 900 [(6-AMINO-4- PYRIMIDINYL)AMINO]BENZENESULFONAMIDE REMARK 900 RELATED ID: 2B52 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH-042562 REMARK 900 RELATED ID: 1KE5 RELATED DB: PDB REMARK 900 CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO- 1,2-DIHYDRO-3H-INDOL-3- REMARK 900 YLIDENE)METHYL] AMINO}BENZENESULFONAMIDE REMARK 900 RELATED ID: 1FIN RELATED DB: PDB REMARK 900 CYCLIN A - CYCLIN-DEPENDENT KINASE 2 COMPLEX REMARK 900 RELATED ID: 2C5O RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C68 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2X1N RELATED DB: PDB REMARK 900 1ST PUBLICATION TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS REMARK 900 OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN 2ND PUBLICATION REMARK 900 DESIGN, SYNTHESIS AND EVALUATION OF 2-METHYL- AND 2-AMINO-N-ARYL-4, REMARK 900 5- DIHYDROTHIAZOLO (4,5-H)QUINAZOLIN-8-AMINES AS RING-CONSTRAINED 2- REMARK 900 ANILINO-4-(THIAZOL-5 -YL)PYRIMIDINE CDK INHIBITORS REMARK 900 RELATED ID: 2VTT RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1P2A RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH REMARK 900 ATRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR REMARK 900 RELATED ID: 2VTQ RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2C4G RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514 REMARK 900 RELATED ID: 1H1Q RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6094 REMARK 900 RELATED ID: 1W0X RELATED DB: PDB REMARK 900 CRYSTALS STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR REMARK 900 OLOMOUCINE. REMARK 900 RELATED ID: 2W05 RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE, REMARK 900 COMPOUND 5B REMARK 900 RELATED ID: 1PXO RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2- REMARK 900 AMINO-4-METHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-(3-NITRO- PHENYL)- REMARK 900 AMINE REMARK 900 RELATED ID: 1KE9 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({ REMARK 900 [AMINO(IMINO)METHYL] AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3- REMARK 900 DIHYDRO-1H-INDOLE REMARK 900 RELATED ID: 2A0C RELATED DB: PDB REMARK 900 HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II, A NOVEL 2,6,9- REMARK 900 TRISUBSTITUTED PURINE CYCLIN -DEPENDENT KINASE INHIBITOR REMARK 900 RELATED ID: 1HCK RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1JSU RELATED DB: PDB REMARK 900 P27(KIP1)/CYCLIN A/CDK2 COMPLEX REMARK 900 RELATED ID: 1PXN RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-[4-(4- REMARK 900 METHYL-2- METHYLAMINO-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL REMARK 900 RELATED ID: 2UZE RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2V0D RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2VTM RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1OIQ RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1H1R RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6086 REMARK 900 RELATED ID: 2IW8 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- CYCLIN A F82H-L83V-H84D REMARK 900 MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR REMARK 900 RELATED ID: 1GIH RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1HCL RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1PW2 RELATED DB: PDB REMARK 900 APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 2WHB RELATED DB: PDB REMARK 900 TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A REMARK 900 THROUGH STRUCTURE GUIDED DESIGN REMARK 900 RELATED ID: 2VTN RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2W06 RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE, REMARK 900 COMPOUND 5C REMARK 900 RELATED ID: 1JST RELATED DB: PDB REMARK 900 PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A REMARK 900 RELATED ID: 1OIU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1B38 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1PXM RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 3-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINO]-PHENOL REMARK 900 RELATED ID: 1FQ1 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) INCOMPLEX REMARK 900 WITH PHOSPHO-CDK2 REMARK 900 RELATED ID: 1VYW RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137 REMARK 900 RELATED ID: 1H1P RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU2058 REMARK 900 RELATED ID: 2WMA RELATED DB: PDB REMARK 900 STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE REMARK 900 LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A REMARK 900 RELATED ID: 2C69 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1URC RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1PXI RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,5- REMARK 900 DICHLORO-THIOPHEN- 3-YL)-PYRIMIDIN-2-YLAMINE REMARK 900 RELATED ID: 2C6I RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2WXV RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO (4,3-H) QUINAZOLINE-3- REMARK 900 CARBOXAMIDE INHIBITOR REMARK 900 RELATED ID: 1YKR RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINEINHIBITOR REMARK 900 RELATED ID: 2W17 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH THE IMIDAZOLE PYRIMIDINE AMIDE, COMPOUND (S)-8B REMARK 900 RELATED ID: 2UZD RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2C6K RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C5Y RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 1WCC RELATED DB: PDB REMARK 900 SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY REMARK 900 RELATED ID: 2J9M RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC REMARK 900 AMINOPYRIMIDINE REMARK 900 RELATED ID: 1VYZ RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227 REMARK 900 RELATED ID: 2VTI RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1JVP RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 ( UNPHOSPHORYLATED) INCOMPLEX WITH REMARK 900 PKF049-365 REMARK 900 RELATED ID: 1W98 RELATED DB: PDB REMARK 900 THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E REMARK 900 RELATED ID: 2WIP RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1-METHYL-4,5- REMARK 900 DIHYDRO-1H- PYRAZOLO[4,3-H] QUINAZOLINE-3-CARBOXYLIC ACID REMARK 900 RELATED ID: 1PKD RELATED DB: PDB REMARK 900 THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN REMARK 900 A REMARK 900 RELATED ID: 1P5E RELATED DB: PDB REMARK 900 THE STRUCURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THEINHIBITOR REMARK 900 4,5,6,7- TETRABROMOBENZOTRIAZOLE (TBS) REMARK 900 RELATED ID: 2VTS RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2C5P RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2UZN RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2B54 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2) COMPLEXED WITH DIN-232305 REMARK 900 RELATED ID: 1KE6 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4-[2-(7- REMARK 900 OXO-6,7-DIHYDRO -8H-[1,3]THIAZOLO[5,4-E]INDOL-8- YLIDENE)HYDRAZINO] REMARK 900 PHENYL}METHANESULFONAMIDE REMARK 900 RELATED ID: 1PXJ RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,4- REMARK 900 DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YLAMINE REMARK 900 RELATED ID: 2UZL RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2CCI RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A REMARK 900 PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6 REMARK 900 RELATED ID: 2BKZ RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611 REMARK 900 RELATED ID: 2G9X RELATED DB: PDB REMARK 900 STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/ CYCLIN A INCOMPLEX WITH REMARK 900 THE INHIBITOR NU6271 REMARK 900 RELATED ID: 1Y91 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1,5-A] REMARK 900 PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2IW6 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- CYCLIN A COMPLEXED WITH A REMARK 900 BISANILINOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1GIJ RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1R78 RELATED DB: PDB REMARK 900 CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR REMARK 900 RELATED ID: 1H0V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 2-AMINO-6-[(R )-PYRROLIDINO-5'-YL]METHOXYPURINE REMARK 900 RELATED ID: 2IW9 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- CYCLIN A COMPLEXED WITH A REMARK 900 BISANILINOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1W8C RELATED DB: PDB REMARK 900 CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY- 8-ISOPROPYL-9H-PURIN-2- REMARK 900 YLAMINE AND MONOMERIC CDK2 REMARK 900 RELATED ID: 1BUH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITHCELL CYCLE- REMARK 900 REGULATORY PROTEIN CKSHS1 REMARK 900 RELATED ID: 2BPM RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529 REMARK 900 RELATED ID: 2BTS RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032 REMARK 900 RELATED ID: 1FVV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLEINHIBITOR REMARK 900 RELATED ID: 1OKW RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR AC-ARG- ARG-LEU-ASN-(M-CL-PHE)-NH2 REMARK 900 RELATED ID: 2A4L RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH ROSCOVITINE REMARK 900 RELATED ID: 2VTP RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2C6T RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1FVT RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH AN REMARK 900 OXINDOLE INHIBITOR REMARK 900 RELATED ID: 1QMZ RELATED DB: PDB REMARK 900 PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX REMARK 900 RELATED ID: 2W1H RELATED DB: PDB REMARK 900 FRAGMENT-BASED DISCOVERY OF THE PYRAZOL-4- YL UREA (AT9283), A REMARK 900 MULTI-TARGETED KINASE INHIBITOR WITH POTENT AURORA KINASE ACTIVITY REMARK 900 RELATED ID: 2XMY RELATED DB: PDB REMARK 900 DISCOVERY AND CHARACTERISATION OF 2-ANILINO- 4-(THIAZOL-5-YL) REMARK 900 PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS REMARK 900 RELATED ID: 2VU3 RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1OGU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 2- REMARK 900 ARYLAMINO-4- CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2B55 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITHINDENOPYRAXOLE REMARK 900 DIN-101312 REMARK 900 RELATED ID: 1PF8 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2COMPLEXED WITH REMARK 900 A NUCLEOSIDE INHIBITOR REMARK 900 RELATED ID: 1H1S RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6102 REMARK 900 RELATED ID: 2JGZ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B REMARK 900 RELATED ID: 2C5V RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2BHE RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 5-BROMO- INDIRUBINE REMARK 900 RELATED ID: 1URW RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-B] PYRIDAZINE REMARK 900 RELATED ID: 1OIY RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 2C6L RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1F5Q RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO REMARK 900 HUMAN CYCLIN DEPENDANT KINASE 2 REMARK 900 RELATED ID: 2C6O RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2VTL RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1OL1 RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-CIT- CIT-LEU-ILE-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1H01 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 2WFY RELATED DB: PDB REMARK 900 TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A REMARK 900 THROUGH STRUCTURE GUIDED DESIGN REMARK 900 RELATED ID: 2UZB RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1OIR RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1OI9 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 2VTJ RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2CJM RELATED DB: PDB REMARK 900 MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 REMARK 900 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE REMARK 900 RELATED ID: 2C5N RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5X RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2WEV RELATED DB: PDB REMARK 900 TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A REMARK 900 THROUGH STRUCTURE GUIDED DESIGN REMARK 900 RELATED ID: 2C6M RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1OIT RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 2V22 RELATED DB: PDB REMARK 900 REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE REMARK 900 INHIBITORS REMARK 900 RELATED ID: 1GY3 RELATED DB: PDB REMARK 900 PCDK2/CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE SUBSTRATE REMARK 900 RELATED ID: 2VV9 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE REMARK 900 RELATED ID: 1GII RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1DI8 RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4- REMARK 900 [3- HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE REMARK 900 RELATED ID: 2WPA RELATED DB: PDB REMARK 900 OPTIMISATION OF 6,6-DIMETHYL PYRROLO 3,4- C PYRAZOLES: REMARK 900 IDENTIFICATION OF PHA-793887, A POTENT CDK INHIBITOR SUITABLE FOR REMARK 900 INTRAVENOUS DOSING REMARK 900 RELATED ID: 1E9H RELATED DB: PDB REMARK 900 THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE REMARK 900 INHIBITOR INDIRUBIN-5- SULPHONATE BOUND REMARK 900 RELATED ID: 2WMB RELATED DB: PDB REMARK 900 STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE REMARK 900 LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A REMARK 900 RELATED ID: 1DM2 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 HYMENIALDISINE REMARK 900 RELATED ID: 2VTO RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1H24 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 E2F REMARK 900 RELATED ID: 2UZO RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2EXM RELATED DB: PDB REMARK 900 HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE REMARK 900 RELATED ID: 1H00 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 2CLX RELATED DB: PDB REMARK 900 4-ARYLAZO-3,5-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY, REMARK 900 CRYSTAL STRUCTURE IN COMPLEX WITH CDK2, SELECTIVITY, AND CELLULAR REMARK 900 EFFECTS REMARK 900 RELATED ID: 1PXP RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'- DIMETHYL-BENZENE-1, REMARK 900 4-DIAMINE REMARK 900 RELATED ID: 2CCH RELATED DB: PDB REMARK 900 THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE REMARK 900 PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA-LINKED ATP ANALOGUE REMARK 900 RELATED ID: 1B39 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160 REMARK 900 RELATED ID: 2BTR RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873 REMARK 900 RELATED ID: 1AQ1 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 STAUROSPORINE REMARK 900 RELATED ID: 1H0W RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 2-AMINO-6-[ CYCLOHEX-3-ENYL]METHOXYPURINE REMARK 900 RELATED ID: 1G5S RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2)IN REMARK 900 COMPLEX WITH THE INHIBITOR H717 REMARK 900 RELATED ID: 1CKP RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 PURVALANOL B REMARK 900 RELATED ID: 1H28 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P107 REMARK 900 RELATED ID: 1PXL RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2,4- REMARK 900 DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YL]-(4-TRIFLUOROMETHYL- PHENYL)- REMARK 900 AMINE REMARK 900 RELATED ID: 1KE8 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO-1,2- REMARK 900 DIHYDRO-3H-INDOL-3 -YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2- YL) REMARK 900 BENZENESULFONAMIDE REMARK 900 RELATED ID: 1H26 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P53 REMARK 900 RELATED ID: 2VTR RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1E1X RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027 REMARK 900 RELATED ID: 1H07 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1Y8Y RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1,5-A] REMARK 900 PYRIMIDINE INHIBITOR DBREF 2XNB A 1 298 UNP P24941 CDK2_HUMAN 1 298 SEQRES 1 A 298 MET GLU ASN PHE GLN LYS VAL GLU LYS ILE GLY GLU GLY SEQRES 2 A 298 THR TYR GLY VAL VAL TYR LYS ALA ARG ASN LYS LEU THR SEQRES 3 A 298 GLY GLU VAL VAL ALA LEU LYS LYS ILE ARG LEU ASP THR SEQRES 4 A 298 GLU THR GLU GLY VAL PRO SER THR ALA ILE ARG GLU ILE SEQRES 5 A 298 SER LEU LEU LYS GLU LEU ASN HIS PRO ASN ILE VAL LYS SEQRES 6 A 298 LEU LEU ASP VAL ILE HIS THR GLU ASN LYS LEU TYR LEU SEQRES 7 A 298 VAL PHE GLU PHE LEU HIS GLN ASP LEU LYS LYS PHE MET SEQRES 8 A 298 ASP ALA SER ALA LEU THR GLY ILE PRO LEU PRO LEU ILE SEQRES 9 A 298 LYS SER TYR LEU PHE GLN LEU LEU GLN GLY LEU ALA PHE SEQRES 10 A 298 CYS HIS SER HIS ARG VAL LEU HIS ARG ASP LEU LYS PRO SEQRES 11 A 298 GLN ASN LEU LEU ILE ASN THR GLU GLY ALA ILE LYS LEU SEQRES 12 A 298 ALA ASP PHE GLY LEU ALA ARG ALA PHE GLY VAL PRO VAL SEQRES 13 A 298 ARG THR TYR THR HIS GLU VAL VAL THR LEU TRP TYR ARG SEQRES 14 A 298 ALA PRO GLU ILE LEU LEU GLY CYS LYS TYR TYR SER THR SEQRES 15 A 298 ALA VAL ASP ILE TRP SER LEU GLY CYS ILE PHE ALA GLU SEQRES 16 A 298 MET VAL THR ARG ARG ALA LEU PHE PRO GLY ASP SER GLU SEQRES 17 A 298 ILE ASP GLN LEU PHE ARG ILE PHE ARG THR LEU GLY THR SEQRES 18 A 298 PRO ASP GLU VAL VAL TRP PRO GLY VAL THR SER MET PRO SEQRES 19 A 298 ASP TYR LYS PRO SER PHE PRO LYS TRP ALA ARG GLN ASP SEQRES 20 A 298 PHE SER LYS VAL VAL PRO PRO LEU ASP GLU ASP GLY ARG SEQRES 21 A 298 SER LEU LEU SER GLN MET LEU HIS TYR ASP PRO ASN LYS SEQRES 22 A 298 ARG ILE SER ALA LYS ALA ALA LEU ALA HIS PRO PHE PHE SEQRES 23 A 298 GLN ASP VAL THR LYS PRO VAL PRO HIS LEU ARG LEU HET Y8L A1299 54 HETNAM Y8L 3,4-DIMETHYL-5-(2-{[(1Z)-4-PIPERAZIN-1-YLCYCLOHEXA-2,4- HETNAM 2 Y8L DIEN-1-YLIDENE]AMINO}PYRIMIDIN-4-YL)-1,3-THIAZOL- HETNAM 3 Y8L 2(3H)-ONE FORMUL 2 Y8L C19 H22 N6 O S FORMUL 3 HOH *260(H2 O) HELIX 1 1 PRO A 45 LYS A 56 1 12 HELIX 2 2 LEU A 87 SER A 94 1 8 HELIX 3 3 PRO A 100 HIS A 121 1 22 HELIX 4 4 GLY A 147 PHE A 152 1 6 HELIX 5 5 ALA A 170 LEU A 175 1 6 HELIX 6 6 THR A 182 ARG A 199 1 18 HELIX 7 7 SER A 207 GLY A 220 1 14 HELIX 8 8 GLY A 229 MET A 233 5 5 HELIX 9 9 ASP A 247 VAL A 252 1 6 HELIX 10 10 ASP A 256 LEU A 267 1 12 HELIX 11 11 SER A 276 LEU A 281 1 6 HELIX 12 12 ALA A 282 GLN A 287 5 6 SHEET 1 AA 5 PHE A 4 GLY A 13 0 SHEET 2 AA 5 GLY A 16 ASN A 23 -1 O GLY A 16 N GLY A 13 SHEET 3 AA 5 VAL A 29 LYS A 34 -1 O VAL A 30 N ALA A 21 SHEET 4 AA 5 LYS A 75 GLU A 81 -1 O LEU A 78 N LYS A 33 SHEET 5 AA 5 LEU A 66 THR A 72 -1 N LEU A 67 O VAL A 79 SHEET 1 AB 3 GLN A 85 ASP A 86 0 SHEET 2 AB 3 LEU A 133 ILE A 135 -1 O ILE A 135 N GLN A 85 SHEET 3 AB 3 ILE A 141 LEU A 143 -1 O LYS A 142 N LEU A 134 CISPEP 1 PRO A 253 PRO A 254 0 8.16 SITE 1 AC1 15 ILE A 10 GLU A 12 VAL A 18 ALA A 31 SITE 2 AC1 15 LYS A 33 PHE A 80 GLU A 81 LEU A 83 SITE 3 AC1 15 HIS A 84 GLN A 85 ASP A 86 LEU A 134 SITE 4 AC1 15 ASP A 145 HOH A2006 HOH A2258 CRYST1 53.005 71.108 72.028 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.018866 0.000000 0.000000 0.00000 SCALE2 0.000000 0.014063 0.000000 0.00000 SCALE3 0.000000 0.000000 0.013883 0.00000 TER 2474 LEU A 298 HETATM 2475 C17AY8L A1299 21.030 24.009 29.256 0.50 43.26 C HETATM 2476 C17BY8L A1299 20.972 24.104 29.298 0.50 59.58 C HETATM 2477 C18AY8L A1299 20.870 22.477 29.251 0.50 41.83 C HETATM 2478 C18BY8L A1299 21.329 22.614 29.393 0.50 58.68 C HETATM 2479 N19AY8L A1299 21.724 21.821 28.249 0.50 33.31 N HETATM 2480 N19BY8L A1299 21.266 21.929 28.083 0.50 52.83 N HETATM 2481 C20AY8L A1299 21.547 22.504 26.975 0.50 35.13 C HETATM 2482 C20BY8L A1299 21.210 22.866 26.953 0.50 55.59 C HETATM 2483 C21AY8L A1299 22.313 23.826 27.037 0.50 38.31 C HETATM 2484 C21BY8L A1299 22.258 23.965 27.150 0.50 54.55 C HETATM 2485 N16AY8L A1299 21.999 24.549 28.282 0.50 28.21 N HETATM 2486 N16BY8L A1299 21.859 24.758 28.324 0.50 50.63 N HETATM 2487 C12AY8L A1299 22.470 25.869 28.457 0.50 39.37 C HETATM 2488 C12BY8L A1299 22.255 26.099 28.473 0.50 51.81 C HETATM 2489 C13AY8L A1299 23.389 26.428 27.566 0.50 31.86 C HETATM 2490 C13BY8L A1299 23.274 26.619 27.679 0.50 47.77 C HETATM 2491 C14AY8L A1299 23.819 27.755 27.710 0.50 40.76 C HETATM 2492 C14BY8L A1299 23.666 27.956 27.807 0.50 45.27 C HETATM 2493 C11AY8L A1299 22.009 26.643 29.518 0.50 30.87 C HETATM 2494 C11BY8L A1299 21.647 26.922 29.414 0.50 48.25 C HETATM 2495 C10AY8L A1299 22.471 27.957 29.661 0.50 36.26 C HETATM 2496 C10BY8L A1299 22.039 28.260 29.530 0.50 44.67 C HETATM 2497 C9 AY8L A1299 23.358 28.543 28.754 0.50 27.04 C HETATM 2498 C9 BY8L A1299 23.052 28.786 28.730 0.50 37.78 C HETATM 2499 N7 AY8L A1299 23.753 29.812 28.968 0.50 35.63 N HETATM 2500 N7 BY8L A1299 23.417 30.067 28.872 0.50 40.29 N HETATM 2501 C4 AY8L A1299 24.842 30.429 28.472 0.50 27.37 C HETATM 2502 C4 BY8L A1299 24.503 30.601 28.298 0.50 36.22 C HETATM 2503 N5 AY8L A1299 25.786 29.832 27.713 0.50 31.61 N HETATM 2504 N5 BY8L A1299 25.301 29.890 27.479 0.50 38.52 N HETATM 2505 N3 AY8L A1299 24.930 31.755 28.691 0.50 42.38 N HETATM 2506 N3 BY8L A1299 24.774 31.894 28.552 0.50 43.56 N HETATM 2507 C2 AY8L A1299 25.945 32.478 28.244 0.50 31.51 C HETATM 2508 C2 BY8L A1299 25.842 32.490 28.047 0.50 33.22 C HETATM 2509 C1 AY8L A1299 26.946 31.872 27.505 0.50 26.98 C HETATM 2510 C1 BY8L A1299 26.668 31.783 27.193 0.50 33.31 C HETATM 2511 C6 AY8L A1299 26.865 30.501 27.258 0.50 35.22 C HETATM 2512 C6 BY8L A1299 26.384 30.447 26.916 0.50 37.63 C HETATM 2513 C15AY8L A1299 27.837 29.897 26.443 0.50 30.22 C HETATM 2514 C15BY8L A1299 27.225 29.764 26.033 0.50 39.44 C HETATM 2515 S23AY8L A1299 29.207 30.663 25.737 0.50 27.68 S HETATM 2516 S23BY8L A1299 26.904 28.383 25.055 0.50 49.71 S HETATM 2517 C24AY8L A1299 29.677 29.286 24.871 0.50 33.30 C HETATM 2518 C24BY8L A1299 28.476 28.414 24.351 0.50 44.67 C HETATM 2519 O28AY8L A1299 30.676 29.188 24.162 0.50 30.84 O HETATM 2520 O28BY8L A1299 28.924 27.627 23.520 0.50 38.00 O HETATM 2521 N25AY8L A1299 28.842 28.279 25.139 0.50 36.20 N HETATM 2522 N25BY8L A1299 29.177 29.432 24.853 0.50 41.90 N HETATM 2523 C29AY8L A1299 29.025 26.926 24.541 0.50 42.71 C HETATM 2524 C29BY8L A1299 30.575 29.708 24.464 0.50 45.06 C HETATM 2525 C26AY8L A1299 27.837 28.572 25.975 0.50 34.39 C HETATM 2526 C26BY8L A1299 28.537 30.160 25.775 0.50 43.20 C HETATM 2527 C27AY8L A1299 26.804 27.516 26.378 0.50 32.30 C HETATM 2528 C27BY8L A1299 29.184 31.349 26.476 0.50 44.93 C HETATM 2529 O HOH A2001 40.371 27.408 44.373 1.00 73.58 O HETATM 2530 O HOH A2002 42.212 35.576 42.978 1.00 47.46 O HETATM 2531 O HOH A2003 41.015 27.735 41.235 1.00 73.16 O HETATM 2532 O HOH A2004 46.283 32.415 40.203 1.00 40.63 O HETATM 2533 O HOH A2005 39.312 37.698 43.173 1.00 80.91 O HETATM 2534 O HOH A2006 20.912 20.808 31.854 1.00 65.67 O HETATM 2535 O HOH A2007 36.113 26.644 40.092 1.00 64.53 O HETATM 2536 O HOH A2008 29.403 23.522 45.490 1.00 84.59 O HETATM 2537 O HOH A2009 28.135 26.154 42.972 1.00 63.94 O HETATM 2538 O HOH A2010 30.108 22.201 41.284 1.00 65.86 O HETATM 2539 O HOH A2011 33.650 20.898 40.014 1.00 74.96 O HETATM 2540 O HOH A2012 21.990 25.895 33.537 1.00 53.94 O HETATM 2541 O HOH A2013 31.243 41.733 35.770 1.00 48.03 O HETATM 2542 O HOH A2014 34.597 16.842 28.882 1.00 56.79 O HETATM 2543 O HOH A2015 23.283 21.464 31.871 1.00 47.04 O HETATM 2544 O HOH A2016 26.819 39.366 34.259 1.00 55.96 O HETATM 2545 O HOH A2017 0.570 34.259 17.390 0.50 34.25 O HETATM 2546 O HOH A2018 27.513 22.523 23.813 1.00 49.56 O HETATM 2547 O HOH A2019 39.065 46.474 21.486 1.00 76.43 O HETATM 2548 O HOH A2020 44.381 38.765 27.875 1.00 55.41 O HETATM 2549 O HOH A2021 20.292 27.507 35.324 1.00 38.43 O HETATM 2550 O HOH A2022 25.000 34.502 43.149 1.00 55.35 O HETATM 2551 O HOH A2023 23.164 27.822 42.488 1.00 61.70 O HETATM 2552 O HOH A2024 31.836 37.949 37.318 1.00 49.96 O HETATM 2553 O HOH A2025 37.096 28.077 43.060 0.50 59.73 O HETATM 2554 O HOH A2026 38.242 28.294 43.522 0.50 70.17 O HETATM 2555 O HOH A2027 52.833 30.502 35.495 1.00 57.58 O HETATM 2556 O HOH A2028 29.941 39.798 37.055 1.00 52.41 O HETATM 2557 O HOH A2029 25.696 40.378 40.321 1.00 52.12 O HETATM 2558 O HOH A2030 17.130 25.046 34.562 1.00 62.30 O HETATM 2559 O HOH A2031 25.698 36.989 33.977 1.00 56.46 O HETATM 2560 O HOH A2032 37.709 23.600 36.332 0.50 43.06 O HETATM 2561 O HOH A2033 1.791 30.461 15.805 0.50 34.25 O HETATM 2562 O HOH A2034 43.976 23.250 33.555 1.00 58.94 O HETATM 2563 O HOH A2035 1.021 33.552 15.732 1.00 90.57 O HETATM 2564 O HOH A2036 1.386 35.710 12.834 1.00 60.63 O HETATM 2565 O HOH A2037 13.549 43.909 18.830 0.50 27.51 O HETATM 2566 O HOH A2038 28.782 49.386 8.062 1.00 46.59 O HETATM 2567 O HOH A2039 30.877 53.613 11.246 1.00 62.78 O HETATM 2568 O HOH A2040 51.224 34.861 24.815 1.00 63.85 O HETATM 2569 O HOH A2041 52.607 32.334 25.522 1.00 63.20 O HETATM 2570 O HOH A2042 20.806 18.513 17.327 1.00 60.45 O HETATM 2571 O HOH A2043 48.129 37.672 16.321 1.00 79.74 O HETATM 2572 O HOH A2044 49.604 32.226 16.572 1.00 74.07 O HETATM 2573 O HOH A2045 45.854 38.781 17.042 1.00 69.86 O HETATM 2574 O HOH A2046 48.534 39.842 17.473 1.00 48.90 O HETATM 2575 O HOH A2047 44.188 42.623 17.195 1.00 88.59 O HETATM 2576 O HOH A2048 44.849 40.864 16.182 1.00 66.71 O HETATM 2577 O HOH A2049 45.223 43.131 23.120 1.00 46.44 O HETATM 2578 O HOH A2050 39.925 45.211 23.488 1.00 48.95 O HETATM 2579 O HOH A2051 42.589 39.945 26.182 1.00 73.30 O HETATM 2580 O HOH A2052 34.303 44.479 27.452 1.00 56.39 O HETATM 2581 O HOH A2053 41.794 42.583 30.050 1.00 58.49 O HETATM 2582 O HOH A2054 35.519 46.939 25.696 1.00 73.65 O HETATM 2583 O HOH A2055 34.149 50.125 19.316 1.00 62.98 O HETATM 2584 O HOH A2056 36.828 51.537 24.323 1.00 75.66 O HETATM 2585 O HOH A2057 31.796 40.216 21.848 1.00 40.61 O HETATM 2586 O HOH A2058 23.984 13.879 13.028 1.00 50.97 O HETATM 2587 O HOH A2059 31.260 48.678 24.393 1.00 47.53 O HETATM 2588 O HOH A2060 30.254 48.553 20.728 1.00 48.20 O HETATM 2589 O HOH A2061 26.407 48.247 19.796 1.00 47.38 O HETATM 2590 O HOH A2062 30.413 41.451 24.282 1.00 38.12 O HETATM 2591 O HOH A2063 20.212 42.529 24.878 1.00 56.64 O HETATM 2592 O HOH A2064 37.060 28.883 -3.062 1.00 49.84 O HETATM 2593 O HOH A2065 27.678 42.019 23.670 1.00 32.12 O HETATM 2594 O HOH A2066 32.589 32.386 -0.596 1.00 58.34 O HETATM 2595 O HOH A2067 31.167 37.767 22.779 1.00 46.11 O HETATM 2596 O HOH A2068 31.257 47.301 28.389 1.00 44.71 O HETATM 2597 O HOH A2069 32.383 43.100 26.810 1.00 40.37 O HETATM 2598 O HOH A2070 32.759 43.564 33.121 1.00 74.63 O HETATM 2599 O HOH A2071 33.617 38.958 35.352 1.00 51.97 O HETATM 2600 O HOH A2072 39.782 42.555 33.323 0.50 45.11 O HETATM 2601 O HOH A2073 43.447 39.960 30.577 1.00 71.56 O HETATM 2602 O HOH A2074 3.063 26.187 12.185 1.00 45.64 O HETATM 2603 O HOH A2075 46.930 38.323 32.851 1.00 50.05 O HETATM 2604 O HOH A2076 43.699 38.164 32.618 1.00 60.90 O HETATM 2605 O HOH A2077 51.691 29.591 38.415 1.00 39.45 O HETATM 2606 O HOH A2078 49.830 34.007 36.078 1.00 49.22 O HETATM 2607 O HOH A2079 51.527 29.892 31.287 1.00 59.73 O HETATM 2608 O HOH A2080 31.014 14.206 11.739 1.00 59.72 O HETATM 2609 O HOH A2081 30.344 9.375 9.824 1.00 51.31 O HETATM 2610 O HOH A2082 37.660 21.215 4.005 1.00 70.60 O HETATM 2611 O HOH A2083 48.834 27.147 35.233 1.00 60.59 O HETATM 2612 O HOH A2084 42.763 28.165 29.069 0.50 39.59 O HETATM 2613 O HOH A2085 39.738 25.234 35.613 1.00 69.73 O HETATM 2614 O HOH A2086 25.584 41.178 31.440 1.00 53.05 O HETATM 2615 O HOH A2087 18.386 34.731 31.238 0.50 32.53 O HETATM 2616 O HOH A2088 17.219 28.069 33.507 1.00 87.01 O HETATM 2617 O HOH A2089 18.212 25.971 30.693 1.00 52.16 O HETATM 2618 O HOH A2090 12.060 26.245 27.164 1.00 36.80 O HETATM 2619 O HOH A2091 21.551 22.277 23.705 1.00 49.09 O HETATM 2620 O HOH A2092 2.295 27.427 -1.625 1.00 49.16 O HETATM 2621 O HOH A2093 1.208 26.609 2.026 1.00 54.55 O HETATM 2622 O HOH A2094 13.357 21.262 26.185 1.00 49.68 O HETATM 2623 O HOH A2095 18.132 20.865 25.173 1.00 57.18 O HETATM 2624 O HOH A2096 10.194 23.959 17.644 1.00 43.79 O HETATM 2625 O HOH A2097 16.089 22.296 18.662 1.00 62.23 O HETATM 2626 O HOH A2098 10.984 18.163 21.602 1.00 55.27 O HETATM 2627 O HOH A2099 11.605 19.450 25.131 1.00 73.69 O HETATM 2628 O HOH A2100 5.684 21.969 22.747 1.00 57.29 O HETATM 2629 O HOH A2101 7.222 28.274 21.948 1.00 50.36 O HETATM 2630 O HOH A2102 6.789 18.116 16.202 1.00 58.71 O HETATM 2631 O HOH A2103 0.585 19.225 19.202 1.00 60.68 O HETATM 2632 O HOH A2104 4.486 27.724 21.356 1.00 51.34 O HETATM 2633 O HOH A2105 2.759 27.702 15.663 1.00 63.35 O HETATM 2634 O HOH A2106 19.599 41.597 -1.848 1.00 56.56 O HETATM 2635 O HOH A2107 2.269 28.220 18.468 1.00 68.16 O HETATM 2636 O HOH A2108 4.743 29.525 13.886 1.00 56.28 O HETATM 2637 O HOH A2109 2.101 31.831 14.658 0.50 25.56 O HETATM 2638 O HOH A2110 7.052 39.552 15.233 1.00 35.65 O HETATM 2639 O HOH A2111 -1.156 44.123 10.828 1.00 54.81 O HETATM 2640 O HOH A2112 2.411 40.128 15.273 1.00 60.52 O HETATM 2641 O HOH A2113 2.740 38.289 19.275 0.30 17.60 O HETATM 2642 O HOH A2114 9.956 46.089 23.275 1.00 53.76 O HETATM 2643 O HOH A2115 4.150 37.833 12.238 1.00 50.20 O HETATM 2644 O HOH A2116 12.271 42.380 18.067 0.50 23.33 O HETATM 2645 O HOH A2117 7.855 26.088 34.290 1.00 55.96 O HETATM 2646 O HOH A2118 16.853 42.390 21.879 1.00 46.22 O HETATM 2647 O HOH A2119 18.185 44.238 18.507 1.00 45.44 O HETATM 2648 O HOH A2120 26.602 44.766 8.124 1.00 35.04 O HETATM 2649 O HOH A2121 27.388 48.651 12.523 1.00 58.72 O HETATM 2650 O HOH A2122 32.233 49.752 11.390 1.00 62.10 O HETATM 2651 O HOH A2123 31.512 48.254 7.632 1.00 67.31 O HETATM 2652 O HOH A2124 37.551 43.549 14.017 1.00 57.33 O HETATM 2653 O HOH A2125 35.536 49.198 13.043 1.00 80.92 O HETATM 2654 O HOH A2126 29.912 42.635 4.862 1.00 67.04 O HETATM 2655 O HOH A2127 38.068 39.942 11.358 1.00 63.53 O HETATM 2656 O HOH A2128 34.243 32.834 14.620 1.00 56.83 O HETATM 2657 O HOH A2129 33.106 26.578 11.537 1.00 53.13 O HETATM 2658 O HOH A2130 28.687 27.248 10.014 1.00 32.83 O HETATM 2659 O HOH A2131 35.893 36.452 12.122 1.00 49.30 O HETATM 2660 O HOH A2132 27.123 26.100 11.942 1.00 34.27 O HETATM 2661 O HOH A2133 29.337 22.986 14.289 1.00 47.60 O HETATM 2662 O HOH A2134 28.080 21.109 17.411 1.00 58.26 O HETATM 2663 O HOH A2135 20.472 21.570 16.258 1.00 42.06 O HETATM 2664 O HOH A2136 23.900 25.657 24.300 1.00 36.38 O HETATM 2665 O HOH A2137 27.625 25.351 21.077 1.00 58.16 O HETATM 2666 O HOH A2138 13.858 35.429 24.570 1.00 31.67 O HETATM 2667 O HOH A2139 19.865 38.582 29.813 1.00 46.75 O HETATM 2668 O HOH A2140 11.368 43.020 26.488 1.00 60.09 O HETATM 2669 O HOH A2141 9.331 40.409 26.469 1.00 71.06 O HETATM 2670 O HOH A2142 24.479 41.424 25.429 1.00 53.39 O HETATM 2671 O HOH A2143 29.790 33.614 23.781 1.00 48.65 O HETATM 2672 O HOH A2144 31.911 34.551 22.025 1.00 50.26 O HETATM 2673 O HOH A2145 39.444 40.857 14.048 1.00106.57 O HETATM 2674 O HOH A2146 40.278 18.065 13.610 1.00 67.46 O HETATM 2675 O HOH A2147 28.110 18.877 18.846 1.00 77.94 O HETATM 2676 O HOH A2148 24.978 16.824 14.467 1.00 40.20 O HETATM 2677 O HOH A2149 22.991 18.971 16.147 1.00 54.90 O HETATM 2678 O HOH A2150 26.501 23.438 11.381 1.00 25.81 O HETATM 2679 O HOH A2151 23.651 23.704 5.608 1.00 31.71 O HETATM 2680 O HOH A2152 32.837 22.721 14.250 1.00 68.21 O HETATM 2681 O HOH A2153 33.541 25.686 9.301 1.00 42.95 O HETATM 2682 O HOH A2154 28.011 28.254 7.450 1.00 29.51 O HETATM 2683 O HOH A2155 36.290 25.078 3.847 1.00 41.14 O HETATM 2684 O HOH A2156 37.465 32.417 6.033 1.00 59.79 O HETATM 2685 O HOH A2157 39.308 29.524 -0.970 0.50 37.25 O HETATM 2686 O HOH A2158 37.235 28.416 10.158 1.00 59.67 O HETATM 2687 O HOH A2159 31.152 32.923 1.438 1.00 31.32 O HETATM 2688 O HOH A2160 26.963 39.392 3.862 1.00 40.85 O HETATM 2689 O HOH A2161 27.643 30.278 10.663 1.00 34.61 O HETATM 2690 O HOH A2162 17.915 23.487 10.181 1.00 25.54 O HETATM 2691 O HOH A2163 14.322 21.563 16.011 1.00 48.99 O HETATM 2692 O HOH A2164 12.274 23.964 15.748 1.00 47.45 O HETATM 2693 O HOH A2165 8.958 26.192 16.147 1.00 45.33 O HETATM 2694 O HOH A2166 6.989 26.917 14.470 1.00 54.38 O HETATM 2695 O HOH A2167 5.627 25.454 13.223 1.00 60.59 O HETATM 2696 O HOH A2168 13.002 22.076 7.748 1.00 42.98 O HETATM 2697 O HOH A2169 15.484 14.225 7.577 1.00 66.90 O HETATM 2698 O HOH A2170 14.858 17.751 13.467 1.00 53.75 O HETATM 2699 O HOH A2171 14.879 17.103 8.952 1.00 51.74 O HETATM 2700 O HOH A2172 14.227 19.115 5.431 1.00 59.13 O HETATM 2701 O HOH A2173 19.726 22.330 8.669 1.00 33.34 O HETATM 2702 O HOH A2174 20.138 12.451 9.661 1.00 47.97 O HETATM 2703 O HOH A2175 26.393 16.918 11.431 1.00 38.40 O HETATM 2704 O HOH A2176 26.880 9.962 6.236 1.00 53.68 O HETATM 2705 O HOH A2177 26.155 8.584 10.920 0.50 22.67 O HETATM 2706 O HOH A2178 27.355 10.471 11.977 0.50 26.62 O HETATM 2707 O HOH A2179 26.704 12.582 12.865 0.50 30.56 O HETATM 2708 O HOH A2180 27.567 8.261 8.885 1.00 64.51 O HETATM 2709 O HOH A2181 30.272 11.689 11.027 1.00 63.06 O HETATM 2710 O HOH A2182 28.065 14.765 11.873 1.00 52.08 O HETATM 2711 O HOH A2183 29.230 10.314 4.098 1.00 56.13 O HETATM 2712 O HOH A2184 36.618 18.067 4.890 1.00 57.59 O HETATM 2713 O HOH A2185 36.179 15.565 6.317 1.00 58.73 O HETATM 2714 O HOH A2186 24.579 11.104 1.273 1.00 47.57 O HETATM 2715 O HOH A2187 17.842 17.066 4.348 1.00 37.84 O HETATM 2716 O HOH A2188 16.252 12.852 3.830 1.00 50.55 O HETATM 2717 O HOH A2189 17.264 17.308 1.662 1.00 37.28 O HETATM 2718 O HOH A2190 19.629 25.398 -8.156 1.00 40.45 O HETATM 2719 O HOH A2191 21.232 24.202 -9.434 1.00 51.12 O HETATM 2720 O HOH A2192 22.988 20.439 -11.344 1.00 56.98 O HETATM 2721 O HOH A2193 20.654 24.831 -12.814 1.00 55.15 O HETATM 2722 O HOH A2194 27.820 23.647 -14.783 1.00 44.63 O HETATM 2723 O HOH A2195 25.201 32.269 -14.380 1.00 52.86 O HETATM 2724 O HOH A2196 30.954 31.909 -5.495 1.00 46.32 O HETATM 2725 O HOH A2197 35.360 29.366 -8.129 1.00 58.98 O HETATM 2726 O HOH A2198 34.932 20.129 -12.140 1.00 54.68 O HETATM 2727 O HOH A2199 32.597 23.484 -15.537 1.00 51.82 O HETATM 2728 O HOH A2200 40.907 19.780 -4.315 1.00 63.26 O HETATM 2729 O HOH A2201 37.624 16.515 -1.931 1.00 45.63 O HETATM 2730 O HOH A2202 40.230 20.499 0.041 1.00 52.73 O HETATM 2731 O HOH A2203 37.221 18.268 -6.550 1.00 48.18 O HETATM 2732 O HOH A2204 27.366 21.177 -11.618 1.00 56.51 O HETATM 2733 O HOH A2205 30.509 19.722 -13.740 1.00 55.68 O HETATM 2734 O HOH A2206 27.402 10.558 -10.530 1.00 64.50 O HETATM 2735 O HOH A2207 28.721 17.065 -14.070 1.00 40.47 O HETATM 2736 O HOH A2208 23.466 12.302 -12.324 1.00 54.42 O HETATM 2737 O HOH A2209 19.637 12.137 -8.796 1.00 59.25 O HETATM 2738 O HOH A2210 15.852 16.964 -5.969 1.00 54.41 O HETATM 2739 O HOH A2211 15.940 15.175 -8.927 1.00 68.25 O HETATM 2740 O HOH A2212 19.190 27.961 -7.456 1.00 59.37 O HETATM 2741 O HOH A2213 4.717 26.204 -6.610 1.00 50.05 O HETATM 2742 O HOH A2214 5.342 22.406 -3.702 1.00 46.22 O HETATM 2743 O HOH A2215 3.721 26.108 1.059 1.00 48.86 O HETATM 2744 O HOH A2216 3.712 32.637 8.052 1.00 62.57 O HETATM 2745 O HOH A2217 4.534 39.633 5.814 1.00 45.41 O HETATM 2746 O HOH A2218 8.756 30.364 -2.338 0.50 39.57 O HETATM 2747 O HOH A2219 10.393 35.332 -4.460 0.50 26.18 O HETATM 2748 O HOH A2220 17.278 30.003 -2.552 1.00 49.90 O HETATM 2749 O HOH A2221 17.761 37.954 -5.188 1.00 56.03 O HETATM 2750 O HOH A2222 19.600 28.098 -3.699 1.00 47.18 O HETATM 2751 O HOH A2223 18.514 30.681 -4.587 1.00 59.67 O HETATM 2752 O HOH A2224 20.524 29.659 -5.703 1.00 38.00 O HETATM 2753 O HOH A2225 29.791 34.227 -8.618 1.00 55.73 O HETATM 2754 O HOH A2226 22.991 31.337 -6.331 1.00 44.47 O HETATM 2755 O HOH A2227 27.271 36.274 -8.786 1.00 48.37 O HETATM 2756 O HOH A2228 26.564 38.121 0.153 1.00 39.26 O HETATM 2757 O HOH A2229 20.052 37.519 -5.372 1.00 45.57 O HETATM 2758 O HOH A2230 23.973 40.394 -1.196 1.00 59.71 O HETATM 2759 O HOH A2231 25.254 37.539 2.668 1.00 31.54 O HETATM 2760 O HOH A2232 22.078 41.776 -0.148 1.00 34.86 O HETATM 2761 O HOH A2233 26.169 44.505 3.430 1.00 69.36 O HETATM 2762 O HOH A2234 25.835 40.610 6.134 1.00 29.26 O HETATM 2763 O HOH A2235 25.330 43.232 6.482 1.00 35.84 O HETATM 2764 O HOH A2236 18.469 47.618 6.534 1.00 85.76 O HETATM 2765 O HOH A2237 23.734 52.634 1.829 0.50 43.93 O HETATM 2766 O HOH A2238 10.481 47.337 5.875 1.00 69.17 O HETATM 2767 O HOH A2239 11.539 45.680 7.028 1.00 39.21 O HETATM 2768 O HOH A2240 5.178 41.918 7.096 1.00 63.98 O HETATM 2769 O HOH A2241 11.031 46.868 10.627 1.00 50.43 O HETATM 2770 O HOH A2242 3.275 47.237 10.366 1.00 61.20 O HETATM 2771 O HOH A2243 3.059 45.886 7.137 1.00 51.70 O HETATM 2772 O HOH A2244 5.547 49.306 6.109 1.00 65.78 O HETATM 2773 O HOH A2245 4.632 40.174 13.908 1.00 45.94 O HETATM 2774 O HOH A2246 0.538 41.532 11.346 1.00 70.70 O HETATM 2775 O HOH A2247 1.893 37.736 10.596 1.00 68.22 O HETATM 2776 O HOH A2248 4.689 45.550 13.848 1.00 67.05 O HETATM 2777 O HOH A2249 3.073 40.460 18.048 0.70 28.43 O HETATM 2778 O HOH A2250 7.817 44.406 23.374 1.00 50.50 O HETATM 2779 O HOH A2251 6.931 44.840 20.203 1.00 38.62 O HETATM 2780 O HOH A2252 15.543 42.361 26.295 1.00 47.82 O HETATM 2781 O HOH A2253 10.804 38.431 21.256 1.00 38.41 O HETATM 2782 O HOH A2254 4.218 38.036 24.156 1.00 37.86 O HETATM 2783 O HOH A2255 6.703 31.411 23.546 1.00 40.50 O HETATM 2784 O HOH A2256 11.696 23.891 28.416 1.00 47.06 O HETATM 2785 O HOH A2257 9.337 28.288 34.766 1.00 50.29 O HETATM 2786 O HOH A2258 19.174 25.342 27.622 1.00 58.09 O HETATM 2787 O HOH A2259 20.353 18.701 28.129 1.00 65.11 O HETATM 2788 O HOH A2260 23.979 18.748 27.136 1.00 60.55 O CONECT 2475 2477 2485 CONECT 2476 2478 2486 CONECT 2477 2475 2479 CONECT 2478 2476 2480 CONECT 2479 2477 2481 CONECT 2480 2478 2482 CONECT 2481 2479 2483 CONECT 2482 2480 2484 CONECT 2483 2481 2485 CONECT 2484 2482 2486 CONECT 2485 2475 2483 2487 CONECT 2486 2476 2484 2488 CONECT 2487 2485 2489 2493 CONECT 2488 2486 2490 2494 CONECT 2489 2487 2491 CONECT 2490 2488 2492 CONECT 2491 2489 2497 CONECT 2492 2490 2498 CONECT 2493 2487 2495 CONECT 2494 2488 2496 CONECT 2495 2493 2497 CONECT 2496 2494 2498 CONECT 2497 2491 2495 2499 CONECT 2498 2492 2496 2500 CONECT 2499 2497 2501 CONECT 2500 2498 2502 CONECT 2501 2499 2503 2505 CONECT 2502 2500 2504 2506 CONECT 2503 2501 2511 CONECT 2504 2502 2512 CONECT 2505 2501 2507 CONECT 2506 2502 2508 CONECT 2507 2505 2509 CONECT 2508 2506 2510 CONECT 2509 2507 2511 CONECT 2510 2508 2512 CONECT 2511 2503 2509 2513 CONECT 2512 2504 2510 2514 CONECT 2513 2511 2515 2525 CONECT 2514 2512 2516 2526 CONECT 2515 2513 2517 CONECT 2516 2514 2518 CONECT 2517 2515 2519 2521 CONECT 2518 2516 2520 2522 CONECT 2519 2517 CONECT 2520 2518 CONECT 2521 2517 2523 2525 CONECT 2522 2518 2524 2526 CONECT 2523 2521 CONECT 2524 2522 CONECT 2525 2513 2521 2527 CONECT 2526 2514 2522 2528 CONECT 2527 2525 CONECT 2528 2526 MASTER 842 0 1 12 8 0 4 6 2666 1 54 23 END